Crossmark

Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effect

Crossref DOI link: https://doi.org/10.1186/s12885-020-06763-y

Published Online: 2020-04-14

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Boegeholz, J.

Brueggen, C. S.

Pauli, C.

Dimitriou, F.

Haralambieva, E.

Dummer, R.

Manz, M. G.

Widmer, C. C.
License Information

Text and Data Mining valid from 2020-04-14

Version of Record valid from 2020-04-14
More Information

Article History

Received: 22 July 2019

Accepted: 17 March 2020

First Online: 14 April 2020

Ethics approval and consent to participate

: Since this manuscript covers a retrospective secondary data analysis, no ethics approval was necessary. Furthermore, both patients gave their written informed consent to use their data.

: Both patients of our center gave their written informed consent for the publication of their data.

: RD has consulting and/or advisory relationships Novartis, Merck Sharp & Dhome (MSD), Bristol-Myers Squibb (BMS), Roche, Amgen, Takeda, Pierre Fabre, Sun Pharma, Sanofi outside the submitted work. All remaining authors have declared no conflicts of interest.

Document is current

Any future updates will be listed below